Edwards Lifesciences: Cheap Against Itself, Expensive Against Everything Else (NYSE:EW)
· seekingalpha.com
Edwards Lifesciences' Q2 saw 13.6% YoY sales growth, but Q3 guidance implies a sequential decline attributed to tough comps, not demand. Read more on EW stock here.
Maya is a lawyer by training whose research centres on under-followed US micro-cap and small-cap equities, with particular emphasis on capital structure, capita...